Trial Profile
A Phase 2, Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Efficacy of Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem in Pediatric Subjects With Complicated Intra-Abdominal Infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 May 2023
Price :
$35
*
At a glance
- Drugs Ceftolozane/tazobactam (Primary) ; Meropenem; Metronidazole
- Indications Intra-abdominal infections
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 29 Mar 2023 Results (n=91) assessing the safety and efficacy of ceftolozane/tazobactam in pediatric participants with complicated intra-abdominal infections, published in the Pediatric Infectious Disease Journal.
- 09 Nov 2020 Status changed from active, no longer recruiting to completed.
- 04 Nov 2020 Status changed from recruiting to active, no longer recruiting.